Increasing measurable residual disease level predicts poorer AML outcomes
Research demonstrates a dose-dependent correlation between measurable residual disease and the likelihood of relapse and poor overall survival among adults with acute myeloid leukaemia who achieve complete remission before undergoing allogeneic haematopoietic cell transplantation.
